Entity

Time filter

Source Type

Rockville, MD, United States

Treadwell T.,Institute for Advanced Wound Care | Kleinman H.K.,George Washington University | Crockford D.,RegeneRx | Hardy M.A.,Columbia University | And 2 more authors.
Annals of the New York Academy of Sciences | Year: 2012

Chronic nonhealing cutaneous wounds are a worldwide problem with no agent able to promote healing. A naturally occurring, endogenous repair molecule, thymosin beta 4 (Tβ4), has many biological activities that promote dermal repair. It is released by platelets at the site of injury and initiates the repair cascade. Tβ4 accelerated dermal healing of full-thickness punch wounds in various animal models, including normal rats and mice, steroid-treated rats, diabetic mice, and aged mice. Furthermore, in two phase 2 clinical trials of stasis and pressure ulcers, it was found to accelerate healing by almost a month in those patients that did heal. Tβ4 likely acts to repair and regenerate wounds by promoting cell migration and stem cell mobilization and differentiation, and by inhibiting inflammation, apoptosis, and infection. We conclude that Tβ4 is a multifunctional regenerative peptide important in dermal repair. © 2012 New York Academy of Sciences.. Source


Patent
RegeneRx | Date: 2015-04-07

Peptide fragments having amino acid sequences corresponding to portions of a thymosin beta 4, a thymosin beta 10 and/or a thymosin beta 15 amino acid sequence are provided, as well as methods of treatment utilizing same.


A composition including a peptide agent including amino acid sequence LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO: 2], a conservative variant thereof, or a stimulating agent that stimulates production of an LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO: 2] peptide, or a conservative variant thereof, the composition including at least one amino acid stabilizing agent or lyophilization bulking agent, the composition being in lyophilized form, or in a form capable of being lyophilized.


Pain or irritation of the eyes, caused by injury due to dry eye syndrome, chemical burns or the like can be accompanied by corneal stromal edema. It has been discovered that administration of thymosin 4 and/or oxidized thymosin 4 to cornea in need of treatment of corneal stromal edema is a useful treatment for decreasing such corneal stromal edema.


Patent
RegeneRx | Date: 2013-02-04

Peptide fragments having amino acid sequences corresponding to portions of a thymosin beta 4, a thymosin beta 10 and/or a thymosin beta 15 amino acid sequence are provided, as well as methods of treatment utilizing same.

Discover hidden collaborations